Icon Wealth Partners LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 6.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 679 shares of the medical research company’s stock after selling 46 shares during the period. Icon Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $401,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Thermo Fisher Scientific by 3.8% in the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company’s stock valued at $20,672,838,000 after purchasing an additional 1,143,333 shares during the last quarter. State Street Corp increased its holdings in Thermo Fisher Scientific by 3.4% in the 4th quarter. State Street Corp now owns 16,223,173 shares of the medical research company’s stock valued at $10,828,875,000 after purchasing an additional 529,712 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Thermo Fisher Scientific by 2.3% in the fourth quarter. Capital Research Global Investors now owns 9,454,032 shares of the medical research company’s stock worth $6,308,097,000 after acquiring an additional 208,075 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 6,403,805 shares of the medical research company’s stock worth $4,261,136,000 after acquiring an additional 214,375 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $2,784,029,000. Hedge funds and other institutional investors own 87.48% of the company’s stock.
In other news, Director Debora L. Spar sold 200 shares of the company’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $544.36, for a total value of $108,872.00. Following the completion of the sale, the director now directly owns 810 shares of the company’s stock, valued at $440,931.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michel Lagarde sold 13,030 shares of the company’s stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $565.04, for a total transaction of $7,362,471.20. Following the completion of the sale, the chief operating officer now directly owns 15,758 shares of the company’s stock, valued at $8,903,900.32. The disclosure for this sale can be found here. Insiders sold 42,561 shares of company stock valued at $23,557,413 over the last ninety days. Corporate insiders own 0.43% of the company’s stock.
Shares of TMO opened at $543.28 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $497.83 and a 1-year high of $672.34. The stock has a market cap of $212.67 billion, a PE ratio of 28.33, a price-to-earnings-growth ratio of 1.85 and a beta of 0.83. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.56 and a quick ratio of 1.10. The firm has a fifty day moving average price of $540.08 and a 200 day moving average price of $571.29.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last announced its quarterly earnings results on Thursday, April 28th. The medical research company reported $7.25 earnings per share for the quarter, beating analysts’ consensus estimates of $6.17 by $1.08. Thermo Fisher Scientific had a net margin of 18.49% and a return on equity of 25.33%. The firm had revenue of $11.82 billion during the quarter, compared to analysts’ expectations of $10.66 billion. During the same period in the previous year, the company earned $7.21 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 19.3% compared to the same quarter last year. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Stockholders of record on Wednesday, June 15th will be issued a $0.30 dividend. The ex-dividend date is Tuesday, June 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.22%. Thermo Fisher Scientific’s payout ratio is 6.26%.
TMO has been the subject of several research reports. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $605.00 to $525.00 in a research note on Monday, April 25th. StockNews.com initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.92.
About Thermo Fisher Scientific: (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating).
Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.